LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24NBRV&src=ctag” target=”_blank”gt;$NBRVlt;/agt; lt;a href=”https://twitter.com/hashtag/CLASSACTION?src=hash” target=”_blank”gt;#CLASSACTIONlt;/agt;–Glancy
Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July
8, 2019 deadline to file a lead plaintiff motion in the class
action filed on behalf of Nabriva Therapeutics plc (“Nabriva” or the
“Company”) (NASDAQ: NBRV)
investors who purchased securities between November 1, 2018 and
April 30, 2019, inclusive (the “Class Period”).
If you are a shareholder who suffered a loss, click here to
participate.
If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, at
310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected],
or visit our website at www.glancylaw.com.
On April 30, 2019, the Company revealed that it had received a Complete
Response Letter (“CRL”) from the U.S. Food and Drug Administration
(“FDA”) for its New Drug Application (“NDA”) for CONTEPO™ (fosfomycin)
for injection for the treatment of complicated urinary tract infections.
According to the CRL, the Company had to address certain “issues related
to facility inspections and manufacturing deficiencies at one of
Nabriva’s contract manufacturers” before the FDA would approve the NDA.
On this news, the Company’s share price fell $0.82 per share, more than
27%, to close at $2.17 per share on May 1, 2019, thereby injuring
investors.
The complaint filed in this class action alleges that the Registration
Statements were false and misleading and omitted to state material
adverse facts. Throughout the Class Period, Defendants made materially
false and/or misleading statements, as well as failed to disclose
material adverse facts about the Company’s business, operations, and
prospects. Specifically, Defendants failed to disclose to investors: (1)
that the Company’s manufacturers failed to meet good manufacturing
practices; (2) that these manufacturers would be subject to inspections
by the FDA in connection with the Company’s NDA; (3) that, as a result
of the manufacturing deficiencies, the Company’s NDA for CONTEPO was
unlikely to be approved by the FDA; and (4) that, as a result of the
foregoing, Defendants’ positive statements about the Company’s business,
operations, and prospects, were materially misleading and/or lacked a
reasonable basis.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased or otherwise acquired Nabriva securities during the
Class Period you may move the Court no later than July 8, 2019 to
request appointment as lead plaintiff in this putative class action
lawsuit. To be a member of the class action you need not take any action
at this time; you may retain counsel of your choice or take no action
and remain an absent member of the class action. If you wish to learn
more about this class action, or if you have any questions concerning
this announcement or your rights or interests with respect to the
pending class action lawsuit, please contact Lesley Portnoy, Esquire, of
GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067
at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected],
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Contacts
Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com
